TY  - BOOK
AU  - Ahmed Mohammad Mohi Eldin Ali
AU  - Foaad Mohammad Abutaleb , 
AU  - Hussain Mostafa Khaled , 
AU  - Nadia Mahmoud Mokhtar , 
TI  - Treatment tailored therapy of diffuse large B-cell non hodgkin's lymphoma / 
PY  - 2012///
CY  - Cairo : 
PB  - Ahmed Mohammad Mohi Eldin Ali , 
KW  - CD20-positive diffuse large B-cell lymphoma
KW  - R-CHOP
KW  - Rituximab
N1  - Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical; Issued also as CD
N2  - CD20-positive diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of new cases of lymphoma. DLBCL is a heterogeneous disease that includes at least two prognostically important subtypes (i.e. germinal center B-cell like [GCB] and non-germinal center B-cell like [non-GCB]). These subtypes initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining
UR  - http://172.23.153.220/th.pdf
ER  -